Global Next-Generation Antibody Therapeutics Market
Use of a new improvised therapeutic antibody to form novel medicines for the treatment of different
diseases includes next-generation antibody therapeutics. Next-generation antibody therapeutics have been
clinically developed for many diseases by pharmaceutical and biotechnology firms. Next-generation
antibody-based therapeutics for the treatment of different medical conditions such as cancer, infectious
diseases, and autoimmune diseases improve the current properties of therapeutic antibodies. For the
reason of their unique pharmacological characteristics, the science and development involved in the
production of next-generation antibodies generate great interest for many biotech and pharmaceutical
companies, increase specificity for established cell types, and low intrinsic toxicity. Sacituzumab govitecan,
an antibody-drug conjugate (ADC) composed of a humanized anti-Trop-2 antibody conjugated to SN38 is
studied for the treatment of patients with metastatic triple-negative breast cancer. Immunomedics, a
pharmaceutical company focusing on the development of antibody-drug conjugates for the treatment of
cancer is planning clinical studies of the ADC in other cancers.
Market Size
- 2019: USD 4,747.22 Million
- 2025: USD 11,924.25 Million
- 2030: USD 29,825.60 Million
- 18.5%
- Oncology
- Autoimmune/Inflammatory
- Antibody-Drug Conjugates (ADCs)
- Bispecific Antibodies
- Increasing investments in healthcare infrastructural development
- Increasing volume of chronic patients
- Development of antibody therapeutics for other diseases
- Bristol-Myers Squibb
- Pfizer
- Roche
- 1. Executive Summary
- 1.1 Regional Market Share
- 1.2 Next-Generation Antibody Therapeutics Market: COVID-19 Outbreak
- 2. Research Methodology
- 2.1 Research Objective
- 2.2 Research Approach
- 2.3 Data Sourcing and Methodology
- 2.4 Primary Research
- 2.5 Secondary Research
- 2.6 Market Size Estimation and Data Triangulation
- 3. Market Characteristics
- 3.1 Market Definition
- 3.2 Key Segmentations
- 3.3 Key Developments
- 3.4 Allied Industry Data: Healthcare Industry
- 4. Recent Developments
- 4.1 Overview
- 4.2 Product Launch
- 4.3 Major Management Change
- 4.4 Mergers & Acquisitions Activities
- 4.5 Latest Technological Advancements
- 5. Export-Import Analysis
- 5.1 Monoclonal Antibody EXIM Data Analysis
- 5.2 Major EXIM Statistics
- 5.3 Antibody EXIM data for the key countries
- 5.3.1 United States
- 5.3.2 China
- 5.3.3 India
- 5.3.4 Germany
- 5.3.5 Spain
- 6. Market Dynamics
- 6.1 Introduction
- 6.2 Growth Drivers
- 6.2.1 Increasing investments in healthcare infrastructural development
- 6.2.2 Increasing volume of chronic patients
- 6.2.3 Government initiatives
- 6.3 Restraints
- 6.3.1 Stringent rules & regulations
- 6.3.2 High cost involved in research and development for developing next-generation antibodies
- 6.4 Opportunities
- 6.4.1 Development of antibody therapeutics for other diseases
- 6.4.2 Mergers and acquisitions by major market players
- 6.5 Trends
- 6.5.1 Advancements in technology
- 6.5.2 Rising demand for ADC technology
- 7. Market Analysis
- 7.1 Porters Five Forces
- 7.1.1 Threat of New Entrants
- 7.1.2 Bargaining Power of Customer
- 7.1.3 Bargaining Power of Suppliers
- 7.1.4 Threat of Substitutes
- 7.1.5 Competitive rivalry
- 7.2 PEST Analysis
- 7.2.1 Political
- 7.2.2 Economic
- 7.2.3 Social
- 7.2.4 Technological
- 8. Market Size & Forecast 2019A-2030F
- 8.1 Global Next-Generation Antibody Therapeutics Market: Overview
- 8.2 Global Conventional Antibody Therapeutics Market: Overview
- 8.3 Regional Market Share
- 8.4 Recent Developments (3 years)
- 9. Market Segmentation by Region
- 9.1 North America
- 9.1.1 North America Next-Generation Antibody Therapeutics Market
- 9.1.2 North America Conventional Antibody Therapeutics Market
- 9.2 Europe
- 9.2.1 Europe Next-Generation Antibody Therapeutic Market
- 9.2.2 Europe Conventional Antibody Therapeutic Market
- 9.3 Asia-Pacific
- 9.3.1 Asia-Pacific Next-Generation Antibody Therapeutics Market
- 9.3.2 Asia-Pacific Conventional Antibody Therapeutics Market
- 9.4 Latin America
- 9.4.1 Latin America Next-Generation Antibody Therapeutics Market
- 9.4.2 Latin America Conventional Antibody Therapeutics Market
- 9.5 Middle-East & Africa
- 9.5.1 Middle-East & Africa Next-Generation Antibody Therapeutics Market
- 9.5.2 Middle-East & Africa Conventional Antibody Therapeutics Market
- 10. Market Snippet
- 10.1 Overview
- 10.2 Global Next-Generation Antibody Therapeutics Market: By Technology
- 10.2.1 By Technology: Antibody-Drug Conjugates (ADCs)
- 10.2.2 By Technology: Bispecific Antibodies
- 10.2.3 By Technology: Fc-engineered Antibodies
- 10.2.4 By Technology: Antibody Fragments
- 10.2.5 By Technology: Antibody-like Proteins
- 10.2.6 By Technology: Biosimilar Antibody Products
- 10.2.7 Market Share, By Technology (2019 –2030)
- 10.3 Global Next-Generation Antibody Therapeutics Market: By Therapeutic Areas
- 10.3.1 By Therapeutics Area: Oncology
- 10.3.2 By Therapeutics Area: Autoimmune /inflammatory
- 10.3.3 Market Share, By Therapeutics Area (2019 –2030)
- 10.4 Global Conventional Antibody Therapeutics Market: By Therapeutic Areas
- 10.4.1 By Therapeutics Area: Oncology
- 10.4.2 By Therapeutics Area: Autoimmune /inflammatory
- 10.4.3 Market Share, By Therapeutics Area (2019 –2030)
- 10.5 Key Insights and Recent Developments
- 11. Competitive Landscape
- 11.1 Overview
- 11.2 Market Share Analysis
- 12. Company Profiles
- 12.1 Amgen, Inc.
- 12.1.1 Company Overview
- 12.1.2 Key Products
- 12.1.3 Financial Overview, 2015-2019 (USD Billion)
- 12.1.4 Total Revenue (%) - By Segments, 2019
- 12.1.6 Total Revenue (%) - By Region, 2019
- 12.1.5 Key Performance Indicators
- 12.1.7 Recent News & Development (last 3 yrs.)
- 12.1.8 Executive Team
- 12.2 AstraZenecan, Inc.
- 12.2.1 Company Overview
- 12.2.2 Key Products
- 12.2.3 Financial Overview, 2015-2019 (USD Billion)
- 12.2.4 Total Revenue (%) - By Segments, 2019
- 12.2.5 Key Performance Indicators
- 12.2.6 Total Revenue (%) - By Region, 2019
- 12.2.7 Recent News & Development (last 3 yrs.)
- 12.2.8 Executive Team
- 12.3 Bayer AG
- 12.3.1 Company Overview
- 12.3.2 Key Products
- 12.3.3 Financial Overview, 2015-2019 (USD Billion)
- 12.3.4 Total Revenue (%) - By Segments, 2019
- 12.3.5 Key Performance Indicators
- 12.3.6 Total Revenue (%) - By Region, 2019
- 12.3.7 Recent News & Development (last 3 yrs)
- 12.3.8 Executive Team
- 12.4 Biogen Inc
- 12.4.1 Company Overview
- 12.4.2 Key Products
- 12.4.3 Financial Overview, 2015-2019 (USD Billion)
- 12.4.4 Total Revenue (%) - By Segments, 2019
- 12.4.5 Key Performance Indicators
- 12.4.6 Total Revenue (%) - By Region, 2019
- 12.4.7 Recent News & Development (last 3 yrs.)
- 12.4.8 Executive Team
- 12.5 Bristol Myers Squibb
- 12.5.1 Company Overview
- 12.5.2 Key Products
- 12.5.3 Financial Overview, 2015-2019 (USD Billion)
- 12.5.4 Total Revenue (%) - By Segment, 2019
- 12.5.5 Key Performance Indicators
- 12.5.6 Total Revenue (%) – By Region, 2019
- 12.5.7 Recent News & Development (last 3 yrs.)
- 12.5.8 Executive Team
- 12.6 Immunogen Inc
- 12.6.1 Company Overview
- 12.6.2 Key Products
- 12.6.3 Financial Overview, 2015-2019 (USD Million)
- 12.6.4 Total Revenue (%) - By Operations,
- 12.6.5 Key Performance Indicator
- 12.6.6 Total Revenue (%) - By Collaborative Partner Segment 2019
- 12.6.7 Recent News & Development (last 3 yrs.)
- 12.6.8 Executive Team
- 12.7 Pfizer Inc.
- 12.7.1 Company Overview
- 12.7.2 Key Products
- 12.7.3 Financial Overview, 2015-2019 (USD Billion)
- 12.7.4 Total Revenue (%) - By Segments, 2019
- 12.7.5 Key Performance Indicators
- 12.7.6 Total Revenue (%) - By Region, 2019
- 12.7.7 Recent News & Development (last 3 yrs.)
- 12.7.8 Executive Team
- 12.8 Roche Holding AG
- 12.8.1 Company Overview
- 12.8.2 Key Products
- 12.8.3 Financial Overview, 2015-2019 (USD Billion)
- 12.8.4 Total Revenue (%) - By Segments, 2019
- 12.8.5 Key Performance Indicators
- 12.8.6 Total Revenue (%) - By Region, 2019
- 12.8.7 Recent News & Development (last 3 yrs.)
- 12.8.8 Executive Team
- 12.9 Seattle Genetics, Inc
- 12.9.1 Company Overview
- 12.9.2 Key Products
- 12.9.3 Financial Overview, 2015-2019 (USD Billion)
- 12.9.4 Total Revenue (%) - By Segments, 2019
- 12.9.5 Key Performance Indicators
- 12.9.6 Total Revenue (%) - By Region, 2019
- 12.9.7 Recent News & Development (last 3 yrs.)
- 12.9.8 Executive Team
- 12.10 Xencor
- 12.10.1 Company Overview
- 12.10.2 Key Products
- 12.10.3 Financial Overview, 2015-2019 (USD Billion)
- 12.10.4 Total Revenue (%) - By Segment, 2019
- 12.10.5 Key Performance Indicator
- 12.10.6 Total Revenue (%) – By Region, 2019
- 12.10.7 Recent News & Development (last 3 yrs.)
- 12.10.8 Executive Team
- 12.11 Kyowa Hakko Kirin
- 12.11.1 Company Overview
- 12.11.2 Key Products
- 12.11.3 Financial Overview, 2015-2019 (USD Billion)
- 12.11.4 Total Revenue (%) - By Segment, 2019
- 12.11.5 Key Performance Indicator
- 12.11.6 Total Revenue (%) - By Region, 2019
- 12.11.7 Recent News & Development (last 3 yrs.)
- 12.11.8 Executive Team
- 12.12 Takeda Pharmaceutical Co Ltd
- 12.12.1 Company Overview
- 12.12.2 Key Products
- 12.12.3 Financial Overview, 2016-2020 (USD Billion)
- 12.12.4 Total Revenue (%) - By Segments, 2019
- 12.12.5 Key Performance Indicators
- 12.12.6 Total Revenue (%) - By Region, 2019
- 12.12.7 Recent News & Development (last 3 yrs.)
- 12.12.8 Executive Team
- 12.13 AbbVie
- 12.13.1 Company Overview
- 12.13.2 Key Products
- 12.13.4 Total Revenue (%) - By Segment, 2019
- 12.13.3 Financial Overview, 2015-2019 (USD Billion)
- 12.13.5 Key Performance Indicator
- 12.13.6 Total Revenue (%) - By Region, 2019
- 12.13.7 Recent News & Development (last 3 yrs.)
- 12.13.8 Executive Team
- 12.14 Johnson & Johnson
- 12.14.1 Company Overview
- 12.14.2 Key Products
- 12.14.3 Financial Overview, 2015-2019 (USD Billion)
- 12.14.4 Total Revenue (%) - By Segments, 2019
- 12.14.5 Key Performance Indicator
- 12.14.6 Total Revenue (%) - By Region, 2019
- 12.14.7 Recent News & Development (last 3 yrs.)
- 12.14.8 Executive Team
- 12.15 Novartis AG
- 12.15.1 Company Overview
- 12.15.2 Key Products
- 12.15.3 Financial Overview, 2015-2019 (USD Billion)
- 12.15.4 Total Revenue (%) - By Segment, 2019
- 12.15.5 Key Performance Indicator
- 12.15.6 Total Revenue (%) - By Region, 2019
- 12.15.7 Recent News & Development (last 3 yrs.)
- 12.15.8 Executive Team
- 13. Appendix
- 13.1 List of Abbreviations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook